Independent informational demo — not the official ChemoCentryx or Amgen website.
Science • Research • Discovery

Exploring the science of targeted therapies.

An independent overview of ChemoCentryx’s scientific history and its work in research focused on inflammatory and autoimmune conditions.

Research approach

Understanding complex biology

ChemoCentryx historically focused on chemoattractant pathways and small-molecule medicines being investigated for serious diseases.

⌘

Targeted pathways

Research centered on chemokine and chemoattractant receptors involved in directing immune-cell activity.

◎

Inflammatory disease

The company’s historical research included inflammatory and autoimmune disorders, including rare diseases.

+

Therapeutic research

Its development work included orally administered small-molecule therapeutic candidates.

Research built around a deeper understanding of biology. ChemoCentryx — company background
Company background

About ChemoCentryx

ChemoCentryx was a biopharmaceutical company founded in 1997. Its research and development activities focused on medicines for inflammatory diseases, autoimmune conditions and cancer.

Amgen completed its acquisition of ChemoCentryx in October 2022. This page is an independent educational overview and is not maintained by either company.

This page is not a medical resource and does not provide medical advice, diagnosis, treatment recommendations, or product claims. For current company information, consult Amgen’s official website.
Further reading

Official information

Use these external sources for authoritative company and historical information.